English
1-Boc-3-Hydroxypiperidine CAS 85275-45-2 Ibrutinib Intermediate Purity ≥98.0% (GC) Featured Image
  • 1-Boc-3-Hydroxypiperidine CAS 85275-45-2 Ibrutinib Intermediate Purity ≥98.0% (GC)
  • 1-Boc-3-Hydroxypiperidine CAS 85275-45-2 Ibrutinib Intermediate Purity ≥98.0% (GC)
  • 1-Boc-3-Hydroxypiperidine CAS 85275-45-2 Ibrutinib Intermediate Purity ≥98.0% (GC)

1-Boc-3-Hydroxypiperidine CAS 85275-45-2 Ibrutinib Intermediate Purity ≥98.0% (GC)

Short Description:

Chemical Name: 1-Boc-3-Hydroxypiperidine 

Synonyms: 1-Boc-3-Piperidinol

CAS: 85275-45-2

Appearance: White to Off-White Crystals

Purity: ≥98.0% (GC)  

Intermediate of Ibrutinib (CAS: 936563-96-1)

Contact: Dr. Alvin Huang    

Mobile/Wechat/WhatsApp: +86-15026746401   

E-Mail: alvin@ruifuchem.com 


Product Detail

Related Products

Product Tags

Description:

Ruifu Chemical is the leading manufacturer of 1-Boc-3-Hydroxypiperidine (CAS: 85275-45-2) with high quality, can be used as an intermediate of Ibrutinib (CAS: 936563-96-1). Ruifu Chemical can provide worldwide delivery, competitive price, small and bulk quantities available. Purchase 1-Boc-3-Hydroxypiperidine, Please contact: alvin@ruifuchem.com 

Intermediates of Ibrutinib:

Ibrutinib CAS 936563-96-1                           
3-Hydroxypiperidine CAS 6859-99-0 
1-Boc-3-Hydroxypiperidine CAS 85275-45-2
(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1
4-Phenoxybenzoic Acid  CAS 2215-77-2
4-Phenoxyphenylboronic Acid CAS 51067-38-0
4-Aminopyrazolo[3,4-d]pyrimidine CAS 2380-63-4
4-Amino-3-Iodo-1H-Pyrazolo[3,4-d]pyrimidine  CAS 151266-23-8 
Ibrutinib Deacryloylpiperidine CAS 330786-24-8 
5-Amino-3-(4-Phenoxyphenyl)-1H-Pyrazole-4-Carbonitrile CAS 330792-70-6

Chemical Properties:

Chemical Name 1-Boc-3-Hydroxypiperidine
Synonyms N-Boc-3-Hydroxypiperidine;1-(tert-Butoxycarbonyl)-3-Hydroxypiperidine; 1-Boc-3-Piperidinol; N-Boc-3-Piperidinol; N-(tert-Butoxycarbonyl)-3-Piperidinol; tert-Butyl 3-Hydroxy-1-Piperidinecarboxylate; Boc-3-Hydroxypiperidine
CAS Number 85275-45-2
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C10H19NO3
Molecular Weight 201.26
Melting Point 65.0~70.0℃ 
Density 1.107±0.06 g/cm3
Shipping Condition Shipped Under Ambient Temperature
COA & MSDS Available
Origin Shanghai, China
Category   Pharmaceutical Intermediates
Brand Ruifu Chemical

Specifications:

Item Specifications Specifications
Appearance White to Off-White Crystals Conforms  
Melting Point 65.0~70.0℃  65.0~67.0℃ 
Purity ≥98.0% (GC) 98.6%
Purity ≥98.0% (with Total Nitrogen) Conforms  
Loss on Drying ≤0.50% 0.26%
Residue on Ignition ≤0.20% 0.08%
Infrared Spectrum Conforms to Structure Conforms  
1 H NMR Spectrum Conforms to Structure Conforms  
Test Standard Enterprise Standard Conforms  
Usage Pharmaceutical Intermediates; Intermediate of Ibrutinib (CAS: 936563-96-1)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture.

Advantages:

1

FAQ:

www.ruifuchem.com

85275-45-2 - Risk and Safety:

Hazard Symbols Xi - Irritant
Risk Codes R36/37/38 - Irritating to eyes, respiratory system and skin.
R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed.
Safety Description
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36 - Wear suitable protective clothing.
S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
WGK Germany 3
Hazard Class IRRITANT

85275-45-2 - Application:

1-Boc-3-Hydroxypiperidine (CAS: 85275-45-2), widely used in organic synthesis, used as a pharmaceutical intermediate in the synthesis of Active Pharmaceutical Ingredient (API) synthesis. 1-Boc-3-Hydroxypiperidine can be used as an Intermediate of Ibrutinib (CAS: 936563-96-1). Ibrutinib is a kind of Bruton tyrosine kinase (BTK) inhibitor, it could be used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Food and Drug Administration (FDA) of USA has speed up approval of Pharmacyclics Corporation and Johnson & Johnson's Imbruvica (generic name: Ibrutinib) came to market to the cure a kind of rarely aggressive leukemia-mantle cell lymphoma (MCL) in 13th November, 2013. Ibrutinib is a new kind of oral Bruton tyrosine kinase (BTK) inhibitor, it was awarded by FDA be a breakthrough drugs in February of 2013, and approved the MCL and CLL treatments in 13th November, 2013 and 12th February, 2014 respectively.

    • Write your message here and send it to us